+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Breast Cancer Drugs Market Size, Share & Trends Analysis Report By Therapy (Targeted, Hormonal), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Cancer Type (Hormone Receptor, HER2+), And Segment Forecasts, 2023-2030

  • PDF Icon

    Report

  • 180 Pages
  • June 2023
  • Region: Global
  • Grand View Research
  • ID: 5846815
Description Jump to:
The global breast cancer drugs market size is expected to reach USD 58.69 billion by 2030, registering a CAGR of 9.09% from 2023 to 2030, according to this report. The growth is majorly attributed to the rising disease prevalence, increasing R&D investments, and initiatives by prominent players. Moreover, the trend towards personalized medicine, which involves tailoring treatment for individual patients based on their genetic makeup, is driving the growth of the market. Advances in genomics and molecular biology have led to the development of targeted therapies, which are more effective and have fewer side effects than traditional chemotherapy. Governments around the world are investing in the research and development of new drugs and treatment options. For instance, the U.S.

National Cancer Institute has established several research programs to develop new drugs and improve the efficacy of existing treatments. Similarly, in January 2023, the Australian government announced an investment of USD 16.01 million in developing targeted treatments for women. The investment is expected to fund 23 projects including research on breast cancer through a grant program by the National Health and Medical Research Council. The increasing participation of non-profit organizations is anticipated to propel the market growth. For instance, in June 2022, Susan G. Komen, a breast cancer organization, announced to receive USD 21 million to support around 48 research projects at 26 academic institutions. The majority of funds are allocated to research on aggressive breast cancers, followed by clinical trials and research on eliminating the disparities in the market.

Furthermore, breast cancer patients have been affected by the pandemic as the risk of complications from COVID-19 increases due to their weakened immune systems. As a result, many patients had to postpone or cancel their treatments, which affected the demand for drugs. Moreover, the economic impact of the pandemic also affected the market. The loss of employment or deduction in the income level impacted the affordability of drugs. This, in turn, resulted in reduced product demand and short to medium-term effects on the market. The cost of drugs has a significant impact on the market. High drug prices can limit their usage and affect demand, while lower prices can increase accessibility and demand. Thus, stakeholders need to balance the need for affordable drugs with the need for continued R&D to improve treatment options.

Breast Cancer Drugs Market Report Highlights

  • The immunotherapy type segment was one of the fastest-growing areas of therapy in the market in 2022. Immunotherapy works by stimulating the patient's immune system to recognize and attack cancer cells. This approach has shown promising results in a variety of types, including breast cancer
  • By type, the hormone receptor segment captured the majority of the market share in 2022. Hormone receptor-positive breast cancer is the most common subtype. As a result, hormone therapy drugs have been a mainstay of treatment
  • The hospital pharmacies distribution channel segment held the largest share in 2022. Hospital pharmacies often have access to a wide range of specialized drugs and therapies as compared to retail pharmacies or other channels
  • In terms of revenue share, North America had a dominant position in the global industry in 2022 owing to the increased prevalence of breast cancer, high healthcare expenditures, and ongoing R&D activities


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology And Scope
1.1 Market Segmentation
1.2 Market Definitions And Objectives
1.2.1 Objective - 1
1.2.2 Objective - 2
1.2.3 Objective - 3
1.3 Research Methodology
1.4 Information Procurement
1.4.1 Purchased Database
1.4.2 Gvr’s Internal Database
1.4.3 Secondary Sources
1.4.4 Primary Research
1.5 Information Or Data Analysis
1.5.1 Data Analysis Models
1.6 Market Formulation & Validation
1.7 Model Details
1.7.1 Commodity Flow Analysis
1.8 List Of Secondary Sources
1.9 List Of Abbreviations
1.10 List Of Primary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Therapy And Cancer Type Snapshot
2.3. Distribution Channel Snapshot
2.4. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation And Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends And Outlook
3.4. Market Dynamics
3.4.1. Increased Incidence And Prevalence Rate Of Cancer Worldwide
3.4.2. High Investment In R&D
3.4.3. Technological Advancement In Cancer Biology & Pharmacology
3.5. Market Restraint Analysis
3.5.1. Stringent Regulatory Guidelines
3.5.2. Expiry Of Patented Drugs
3.5.3. Complications Associated With Chemotherapy
3.6. Penetration And Growth Prospect Mapping 2022
3.7. Business Environment Analysis
3.7.1. Swot Analysis; By Factor (Political & Legal, Economic And Technological)
3.7.2. Porter’s Five Forces Analysis
3.8. Covid-19 Impact Analysis
Chapter 4. Therapy Business Analysis
4.1. Breast Cancer Drugs Market: Therapy Movement Analysis
4.2. Targeted Therapy
4.2.1. Breast Cancer Drugs Market, Targeted Therapy, 2018 - 2030 (USD Million)
4.2.2. Abemaciclib
4.2.2.1. Breast Cancer Drugs Market, Abemaciclib, 2018 - 2030 (USD Million)
4.2.3. Ado-Trastuzumab Emtansine
4.2.3.1. Breast Cancer Drugs Market, Ado-Trastuzumab Emtansine, 2018 - 2030 (USD Million)
4.2.4. Everolimus
4.2.4.1. Breast Cancer Drugs Market, Everolimus, 2018 - 2030 (USD Million)
4.2.5. Trastuzumab
4.2.5.1. Breast Cancer Drugs Market, Trastuzumab, 2018 - 2030 (USD Million)
4.2.6. Ribociclib
4.2.6.1. Breast Cancer Drugs Market, Ribociclib, 2018 - 2030 (USD Million)
4.2.7. Palbociclib
4.2.7.1. Breast Cancer Drugs Market, Palbociclib, 2018 - 2030 (USD Million)
4.2.8. Pertuzumab
4.2.8.1. Breast Cancer Drugs Market, Pertuzumab, 2018 - 2030 (USD Million)
4.2.9. Olaparib
4.2.9.1. Breast Cancer Drugs Market, Olaparib, 2018 - 2030 (USD Million)
4.2.10. Others
4.2.10.1. Breast Cancer Drugs Market, Others, 2018 - 2030 (USD Million)
4.3. Hormonal Therapy
4.3.1. Breast Cancer Drugs Market, Hormonal Therapy, 2018 - 2030 (USD Million)
4.3.2. Selective Estrogen Receptor Modulators (Serms)
4.3.2.1. Breast Cancer Drugs Market, Selective Estrogen Receptor Modulators (Serms), 2018 - 2030 (USD Million)
4.3.3. Aromatase Inhibitors
4.3.3.1. Breast Cancer Drugs Market, Aromatase Inhibitors, 2018 - 2030 (USD Million)
4.3.4. Estrogen Receptor Down Regulators (Erds)
4.3.4.1. Breast Cancer Drugs Market, Estrogen Receptor Down Regulators (Erds), 2018 - 2030 (USD Million)
4.4. Chemotherapy
4.4.1. Breast Cancer Drugs Market, Chemotherapy, 2018 - 2030 (USD Million)
4.5. Immunotherapy
4.5.1. Breast Cancer Drugs Market, Immunotherapy, 2018 - 2030 (USD Million)
Chapter 5. Cancer Type Business Analysis
5.1. Breast Cancer Drugs Market: Cancer Type Movement Analysis
5.2. Hormone Receptor
5.2.1. Breast Cancer Drugs Market, Hormone Receptor, 2018 - 2030 (USD Million)
5.3. Her2+
5.3.1. Breast Cancer Drugs Market, Her2+, 2018 - 2030 (USD Million)
Chapter 6. Distribution Channel Business Analysis
6.1. Breast Cancer Drugs Market: Distribution Channel Movement Analysis
6.2. Hospital Pharmacies
6.2.1. Breast Cancer Drugs Market, Hospital Pharmacies, 2018 - 2030 (USD Million)
6.3. Retail Pharmacies
6.3.1. Breast Cancer Drugs Market, Retail Pharmacies, 2018 - 2030 (USD Million)
6.4. Others
6.4.1. Breast Cancer Drugs Market, Others, 2018 - 2030 (USD Million)
Chapter 7. Regional Business Analysis
7.1. Breast Cancer Drugs Market Share By Region, 2022 & 2030
7.2. North America
7.2.1. Swot Analysis
7.2.2. North America Breast Cancer Drugs Market, By Therapy, 2018 - 2030 (USD Million)
7.2.3. North America Breast Cancer Drugs Market, By Cancer Type, 2018 - 2030 (USD Million)
7.2.4. North America Breast Cancer Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
7.2.5. U.S.
7.2.5.1. Key Country Dynamics
7.2.5.2. Target Disease Prevalence
7.2.5.3. Competitive Scenario
7.2.5.4. Regulatory Framework
7.2.5.5. Reimbursement Scenario
7.2.5.6. U.S. Breast Cancer Drugs Market 2018 - 2030 (USD Million)
7.2.6. Canada
7.2.6.1. Key Country Dynamics
7.2.6.2. Target Disease Prevalence
7.2.6.3. Competitive Scenario
7.2.6.4. Regulatory Framework
7.2.6.5. Reimbursement Scenario
7.2.6.6. Canada Breast Cancer Drugs Market 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Swot Analysis
7.3.2. Europe Breast Cancer Drugs Market, By Therapy, 2018 - 2030 (USD Million)
7.3.3. Europe Breast Cancer Drugs Market, By Cancer Type, 2018 - 2030 (USD Million)
7.3.4. Europe Breast Cancer Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
7.3.5. Germany
7.3.5.1. Key Country Dynamics
7.3.5.2. Target Disease Prevalence
7.3.5.3. Competitive Scenario
7.3.5.4. Regulatory Framework
7.3.5.5. Reimbursement Scenario
7.3.5.6. Germany Breast Cancer Drugs Market 2018 - 2030 (USD Million)
7.3.6. Uk
7.3.6.1. Key Country Dynamics
7.3.6.2. Target Disease Prevalence
7.3.6.3. Competitive Scenario
7.3.6.4. Regulatory Framework
7.3.6.5. Reimbursement Scenario
7.3.6.6. Uk Breast Cancer Drugs Market 2018 - 2030 (USD Million)
7.3.7. France
7.3.7.1. Key Country Dynamics
7.3.7.2. Target Disease Prevalence
7.3.7.3. Competitive Scenario
7.3.7.4. Regulatory Framework
7.3.7.5. Reimbursement Scenario
7.3.7.6. France Breast Cancer Drugs Market 2018 - 2030 (USD Million)
7.3.8. Italy
7.3.8.1. Key Country Dynamics
7.3.8.2. Target Disease Prevalence
7.3.8.3. Competitive Scenario
7.3.8.4. Regulatory Framework
7.3.8.5. Reimbursement Scenario
7.3.8.6. Italy Breast Cancer Drugs Market 2018 - 2030 (USD Million)
7.3.9. Spain
7.3.9.1. Key Country Dynamics
7.3.9.2. Target Disease Prevalence
7.3.9.3. Competitive Scenario
7.3.9.4. Regulatory Framework
7.3.9.5. Reimbursement Scenario
7.3.9.6. Spain Breast Cancer Drugs Market 2018 - 2030 (USD Million)
7.3.10. Denmark
7.3.10.1. Key Country Dynamics
7.3.10.2. Target Disease Prevalence
7.3.10.3. Competitive Scenario
7.3.10.4. Regulatory Framework
7.3.10.5. Reimbursement Scenario
7.3.10.6. Denmark Breast Cancer Drugs Market 2018 - 2030 (USD Million)
7.3.11. Sweden
7.3.11.1. Key Country Dynamics
7.3.11.2. Target Disease Prevalence
7.3.11.3. Competitive Scenario
7.3.11.4. Regulatory Framework
7.3.11.5. Reimbursement Scenario
7.3.11.6. Sweden Breast Cancer Drugs Market 2018 - 2030 (USD Million)
7.3.12. Norway
7.3.12.1. Key Country Dynamics
7.3.12.2. Target Disease Prevalence
7.3.12.3. Competitive Scenario
7.3.12.4. Regulatory Framework
7.3.12.5. Reimbursement Scenario
7.3.12.6. Norway Breast Cancer Drugs Market 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Swot Analysis
7.4.2. Asia Pacific Breast Cancer Drugs Market, By Therapy, 2018 - 2030 (USD Million)
7.4.3. Asia Pacific Breast Cancer Drugs Market, By Cancer Type, 2018 - 2030 (USD Million)
7.4.4. Asia Pacific Breast Cancer Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
7.4.5. Japan
7.4.5.1. Key Country Dynamics
7.4.5.2. Target Disease Prevalence
7.4.5.3. Competitive Scenario
7.4.5.4. Regulatory Framework
7.4.5.5. Reimbursement Scenario
7.4.5.6. Japan Breast Cancer Drugs Market 2018 - 2030 (USD Million)
7.4.6. China
7.4.6.1. Key Country Dynamics
7.4.6.2. Target Disease Prevalence
7.4.6.3. Competitive Scenario
7.4.6.4. Regulatory Framework
7.4.6.5. Reimbursement Scenario
7.4.6.6. China Breast Cancer Drugs Market 2018 - 2030 (USD Million)
7.4.7. India
7.4.7.1. Key Country Dynamics
7.4.7.2. Target Disease Prevalence
7.4.7.3. Competitive Scenario
7.4.7.4. Regulatory Framework
7.4.7.5. Reimbursement Scenario
7.4.7.6. India Breast Cancer Drugs Market 2018 - 2030 (USD Million)
7.4.8. South Korea
7.4.8.1. Key Country Dynamics
7.4.8.2. Target Disease Prevalence
7.4.8.3. Competitive Scenario
7.4.8.4. Regulatory Framework
7.4.8.5. Reimbursement Scenario
7.4.8.6. South Korea Breast Cancer Drugs Market 2018 - 2030 (USD Million)
7.4.9. Australia
7.4.9.1. Key Country Dynamics
7.4.9.2. Target Disease Prevalence
7.4.9.3. Competitive Scenario
7.4.9.4. Regulatory Framework
7.4.9.5. Reimbursement Scenario
7.4.9.6. Australia Breast Cancer Drugs Market 2018 - 2030 (USD Million)
7.4.10. Thailand
7.4.10.1. Key Country Dynamics
7.4.10.2. Target Disease Prevalence
7.4.10.3. Competitive Scenario
7.4.10.4. Regulatory Framework
7.4.10.5. Reimbursement Scenario
7.4.10.6. Thailand Breast Cancer Drugs Market 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Swot Analysis
7.5.2. Latin America Breast Cancer Drugs Market, By Therapy, 2018 - 2030 (USD Million)
7.5.3. Latin America Breast Cancer Drugs Market, By Cancer Type, 2018 - 2030 (USD Million)
7.5.4. Latin America Breast Cancer Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
7.5.5. Brazil
7.5.5.1. Key Country Dynamics
7.5.5.2. Target Disease Prevalence
7.5.5.3. Competitive Scenario
7.5.5.4. Regulatory Framework
7.5.5.5. Reimbursement Scenario
7.5.5.6. Brazil Breast Cancer Drugs Market 2018 - 2030 (USD Million)
7.5.6. Mexico
7.5.6.1. Key Country Dynamics
7.5.6.2. Target Disease Prevalence
7.5.6.3. Competitive Scenario
7.5.6.4. Regulatory Framework
7.5.6.5. Reimbursement Scenario
7.5.6.6. Mexico Breast Cancer Drugs Market 2018 - 2030 (USD Million)
7.5.7. Argentina
7.5.7.1. Key Country Dynamics
7.5.7.2. Target Disease Prevalence
7.5.7.3. Competitive Scenario
7.5.7.4. Regulatory Framework
7.5.7.5. Reimbursement Scenario
7.5.7.6. Argentina Breast Cancer Drugs Market 2018 - 2030 (USD Million)
7.6. MEA
7.6.1. Swot Analysis
7.6.2. MEA Breast Cancer Drugs Market, By Therapy, 2018 - 2030 (USD Million)
7.6.3. MEA Breast Cancer Drugs Market, By Cancer Type, 2018 - 2030 (USD Million)
7.6.4. MEA Breast Cancer Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
7.6.5. South Africa
7.6.5.1. Key Country Dynamics
7.6.5.2. Target Disease Prevalence
7.6.5.3. Competitive Scenario
7.6.5.4. Regulatory Framework
7.6.5.5. Reimbursement Scenario
7.6.5.6. South Africa Breast Cancer Drugs Market 2018 - 2030 (USD Million)
7.6.6. Saudi Arabia
7.6.6.1. Key Country Dynamics
7.6.6.2. Target Disease Prevalence
7.6.6.3. Competitive Scenario
7.6.6.4. Regulatory Framework
7.6.6.5. Reimbursement Scenario
7.6.6.6. Saudi Arabia Breast Cancer Drugs Market 2018 - 2030 (USD Million)
7.6.7. UAE
7.6.7.1. Key Country Dynamics
7.6.7.2. Target Disease Prevalence
7.6.7.3. Competitive Scenario
7.6.7.4. Regulatory Framework
7.6.7.5. Reimbursement Scenario
7.6.7.6. UAE Breast Cancer Drugs Market 2018 - 2030 (USD Million)
7.6.8. Kuwait
7.6.8.1. Key Country Dynamics
7.6.8.2. Target Disease Prevalence
7.6.8.3. Competitive Scenario
7.6.8.4. Regulatory Framework
7.6.8.5. Reimbursement Scenario
7.6.8.6. Kuwait Breast Cancer Drugs Market 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1 Company Categorization
8.2 Strategy Mapping
8.2.1 New Product Launch
8.2.2 Partnerships
8.2.3 Acquisition
8.2.4 Collaboration
8.2.5 Funding
8.3 Company Market Share Analysis, 2022
8.4 Company Profiles
8.4.1 Novartis Ag
8.4.1.1 Company Overview
8.4.1.2 Financial Performance
8.4.1.3 Product Benchmarking
8.4.1.4 Strategic Initiatives
8.4.2 Pfizer, Inc
8.4.2.1 Company Overview
8.4.2.2 Financial Performance
8.4.2.3 Product Benchmarking
8.4.2.4 Strategic Initiatives
8.4.3 Merck Kgaa
8.4.3.1 Company Overview
8.4.3.2 Financial Performance
8.4.3.3 Product Benchmarking
8.4.3.4 Strategic Initiatives
8.4.4 Janssen Pharmaceuticals, Inc.
8.4.4.1 Company Overview
8.4.4.2 Financial Performance
8.4.4.3 Product Benchmarking
8.4.4.4 Strategic Initiatives
8.4.5 Celgene Corporation, Inc.
8.4.5.1 Company Overview
8.4.5.2 Financial Performance
8.4.5.3 Product Benchmarking
8.4.5.4 Strategic Initiatives
8.4.6 Genzyme Corporation
8.4.6.1 Company Overview
8.4.6.2 Financial Performance
8.4.6.3 Product Benchmarking
8.4.6.4 Strategic Initiatives
8.4.7 F. Hoffmann-La Roche Ltd
8.4.7.1 Company Overview
8.4.7.2 Financial Performance
8.4.7.3 Product Benchmarking
8.4.7.4 Strategic Initiatives
8.4.8 Astrazeneca
8.4.8.1 Company Overview
8.4.8.2 Financial Performance
8.4.8.3 Product Benchmarking
8.4.8.4 Strategic Initiatives
8.4.9 Abbvie Inc.
8.4.9.1 Company Overview
8.4.9.2 Financial Performance
8.4.9.3 Product Benchmarking
8.4.9.4 Strategic Initiatives
8.4.10 Bristol-Myers Squibb Company
8.4.10.1 Company Overview
8.4.10.2 Financial Performance
8.4.10.3 Product Benchmarking
8.4.10.4 Strategic Initiatives
8.4.11 Macrogenics, Inc.
8.4.11.1 Company Overview
8.4.11.2 Financial Performance
8.4.11.3 Product Benchmarking
8.4.11.4 Strategic Initiatives
8.4.12 Celldex Therapeutics
8.4.12.1 Company Overview
8.4.12.2 Financial Performance
8.4.12.3 Product Benchmarking
8.4.12.4 Strategic Initiatives
8.4.13 Onyx Pharmaceuticals Inc.
8.4.13.1 Company Overview
8.4.13.2 Financial Performance
8.4.13.3 Product Benchmarking
8.4.13.4 Strategic Initiatives
Chapter 9 Conclusion
List of Tables
Table 1: List of Secondary Sources
Table 2: List of Abbreviations
Table 3: Global Breast Cancer Drugs Market, by Region, 2018-2030 (USD Million)
Table 4: Global Breast Cancer Drugs Market, by Therapy, 2018-2030 (USD Million)
Table 5: Global Breast Cancer Drugs Market, by Cancer Type, 2018-2030 (USD Million)
Table 6: Global Breast Cancer Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 7: North America Breast Cancer Drugs Market, by Country, 2018-2030 (USD Million)
Table 8: North America Breast Cancer Drugs Market, by Therapy, 2018-2030 (USD Million)
Table 9: North America Breast Cancer Drugs Market, by Cancer Type, 2018-2030 (USD Million)
Table 10: North America Breast Cancer Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 11: U.S. Breast Cancer Drugs Market, by Therapy, 2018-2030 (USD Million)
Table 12: U.S. Breast Cancer Drugs Market, by Cancer Type, 2018-2030 (USD Million)
Table 13: U.S. Breast Cancer Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 14: Canada Breast Cancer Drugs Market, by Therapy, 2018-2030 (USD Million)
Table 15: Canada Breast Cancer Drugs Market, by Cancer Type, 2018-2030 (USD Million)
Table 16: Canada Breast Cancer Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 17: Canada Breast Cancer Drugs Market, by Therapy, 2018-2030 (USD Million)
Table 18: Canada Breast Cancer Drugs Market, by Cancer Type, 2018-2030 (USD Million)
Table 19: Europe Breast Cancer Drugs Market, by Country, 2018-2030 (USD Million)
Table 20: Europe Breast Cancer Drugs Market, by Therapy, 2018-2030 (USD Million)
Table 21: Europe Breast Cancer Drugs Market, by Cancer Type, 2018-2030 (USD Million)
Table 22: Europe Breast Cancer Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 23: Germany Breast Cancer Drugs Market, by Therapy, 2018-2030 (USD Million)
Table 24: Germany Breast Cancer Drugs Market, by Cancer Type, 2018-2030 (USD Million)
Table 25: Germany Breast Cancer Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 26: UK Breast Cancer Drugs Market, by Therapy, 2018-2030 (USD Million)
Table 27: UK Breast Cancer Drugs Market, by Cancer Type, 2018-2030 (USD Million)
Table 28: UK Breast Cancer Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 29: France Breast Cancer Drugs Market, by Therapy, 2018-2030 (USD Million)
Table 30: France Breast Cancer Drugs Market, by Cancer Type, 2018-2030 (USD Million)
Table 31: France Breast Cancer Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 32: Italy Breast Cancer Drugs Market, by Therapy, 2018-2030 (USD Million)
Table 33: Italy Breast Cancer Drugs Market, by Cancer Type, 2018-2030 (USD Million)
Table 34: Italy Breast Cancer Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 35: Spain Breast Cancer Drugs Market, by Therapy, 2018-2030 (USD Million)
Table 36: Spain Breast Cancer Drugs Market, by Cancer Type, 2018-2030 (USD Million)
Table 37: Spain Breast Cancer Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 38: Denmark Breast Cancer Drugs Market, by Therapy, 2018-2030 (USD Million)
Table 39: Denmark Breast Cancer Drugs Market, by Cancer Type, 2018-2030 (USD Million)
Table 40: Denmark Breast Cancer Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 41: Sweden Breast Cancer Drugs Market, by Therapy, 2018-2030 (USD Million)
Table 42: Sweden Breast Cancer Drugs Market, by Cancer Type, 2018-2030 (USD Million)
Table 43: Sweden Breast Cancer Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 44: Norway Breast Cancer Drugs Market, by Therapy, 2018-2030 (USD Million)
Table 45: Norway Breast Cancer Drugs Market, by Cancer Type, 2018-2030 (USD Million)
Table 46: Norway Breast Cancer Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 47: Asia Pacific Breast Cancer Drugs Market, by Country, 2018-2030 (USD Million)
Table 48: Asia Pacific Breast Cancer Drugs Market, by Therapy, 2018-2030 (USD Million)
Table 49: Asia Pacific Breast Cancer Drugs Market, by Cancer Type, 2018-2030 (USD Million)
Table 50: Asia Pacific Breast Cancer Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 51: China Breast Cancer Drugs Market, by Therapy, 2018-2030 (USD Million)
Table 52: China Breast Cancer Drugs Market, by Cancer Type, 2018-2030 (USD Million)
Table 53: China Breast Cancer Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 54: Japan Breast Cancer Drugs Market, by Therapy, 2018-2030 (USD Million)
Table 55: Japan Breast Cancer Drugs Market, by Cancer Type, 2018-2030 (USD Million)
Table 56: Japan Breast Cancer Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 57: India Breast Cancer Drugs Market, by Therapy, 2018-2030 (USD Million)
Table 58: India Breast Cancer Drugs Market, by Cancer Type, 2018-2030 (USD Million)
Table 59: India Breast Cancer Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 60: South Korea Breast Cancer Drugs Market, by Therapy, 2018-2030 (USD Million)
Table 61: South Korea Breast Cancer Drugs Market, by Cancer Type, 2018-2030 (USD Million)
Table 62: South Korea Breast Cancer Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 63: Australia Breast Cancer Drugs Market, by Therapy, 2018-2030 (USD Million)
Table 64: Australia Breast Cancer Drugs Market, by Cancer Type, 2018-2030 (USD Million)
Table 65: Australia Breast Cancer Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 66: Thailand Breast Cancer Drugs Market, by Therapy, 2018-2030 (USD Million)
Table 67: Thailand Breast Cancer Drugs Market, by Cancer Type, 2018-2030 (USD Million)
Table 68: Thailand Breast Cancer Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 69: Latin America Breast Cancer Drugs Market, by Country, 2018-2030 (USD Million)
Table 70: Latin America Breast Cancer Drugs Market, by Therapy, 2018-2030 (USD Million)
Table 71: Latin America Breast Cancer Drugs Market, by Cancer Type, 2018-2030 (USD Million)
Table 72: Latin America Breast Cancer Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 73: Brazil Breast Cancer Drugs Market, by Therapy, 2018-2030 (USD Million)
Table 74: Brazil Breast Cancer Drugs Market, by Cancer Type, 2018-2030 (USD Million)
Table 75: Brazil Breast Cancer Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 76: Mexico Breast Cancer Drugs Market, by Therapy, 2018-2030 (USD Million)
Table 77: Mexico Breast Cancer Drugs Market, by Cancer Type, 2018-2030 (USD Million)
Table 78: Mexico Breast Cancer Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 79: Argentina Breast Cancer Drugs Market, by Therapy, 2018-2030 (USD Million)
Table 80: Argentina Breast Cancer Drugs Market, by Cancer Type, 2018-2030 (USD Million)
Table 81: Argentina Breast Cancer Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 82: Middle East & Africa Breast Cancer Drugs Market, by Country, 2018-2030 (USD Million)
Table 83: Middle East & Africa Breast Cancer Drugs Market, by Therapy, 2018-2030 (USD Million)
Table 84: Middle East & Africa Breast Cancer Drugs Market, by Cancer Type, 2018-2030 (USD Million)
Table 85: Middle East & Africa Breast Cancer Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 86: South Africa Breast Cancer Drugs Market, by Therapy, 2018-2030 (USD Million)
Table 87: South Africa Breast Cancer Drugs Market, by Cancer Type, 2018-2030 (USD Million)
Table 88: South Africa Breast Cancer Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 89: Saudi Arabia Breast Cancer Drugs Market, by Therapy, 2018-2030 (USD Million)
Table 90: Saudi Arabia Breast Cancer Drugs Market, by Cancer Type, 2018-2030 (USD Million)
Table 91: Saudi Arabia Breast Cancer Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 92: UAE Breast Cancer Drugs Market, by Therapy, 2018-2030 (USD Million)
Table 93: UAE Breast Cancer Drugs Market, by Cancer Type, 2018-2030 (USD Million)
Table 94: UAE Breast Cancer Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 95: Kuwait Breast Cancer Drugs Market, by Therapy, 2018-2030 (USD Million)
Table 96: Kuwait Breast Cancer Drugs Market, by Cancer Type, 2018-2030 (USD Million)
Table 97: Kuwait Breast Cancer Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 98: Financial performance
Table 99: Key companies undergoing expansions
Table 100: Key companies undergoing acquisitions
Table 101: Key companies undergoing collaborations
Table 102: Key companies launching new products/services
Table 103: Key companies undergoing partnerships
Table 104: Key companies undertaking other strategies
List of Figures
Fig. 1: Information Procurement
Fig. 2: Primary Research Pattern
Fig. 3: Market Research Approaches
Fig. 4: Value Chain-Based Sizing & Forecasting
Fig. 5: Market Formulation & Validation
Fig. 6: Breast Cancer Drugs Market Segmentation
Fig. 7: Market Snapshot, 2022
Fig. 8: Market Trends & Outlook
Fig. 9: Market Driver Relevance Analysis (Current & Future Impact)
Fig. 10: Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 11: Market Challenge Relevance Analysis (Current & Future Impact)
Fig. 12: SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 13: Porter’s Five Forces Analysis
Fig. 14: Market Penetration Vs Growth Prospect Mapping, 2022
Fig. 15: Global Breast Cancer Drugs: By Therapy, Movement Analysis
Fig. 16: Global Breast Cancer Drugs Market, for Targeted Therapy, 2018-2030 (USD Million)
Fig. 17: Global Breast Cancer Drugs Market, for Abemaciclib, 2018-2030 (USD Million)
Fig. 18: Global Breast Cancer Drugs Market, for Ado-Trastuzumab Emtansine, 2018-2030 (USD Million)
Fig. 19: Global Breast Cancer Drugs Market, for Everolimus, 2018-2030 (USD Million)
Fig. 20: Global Breast Cancer Drugs Market, for Trastuzumab, 2018-2030 (USD Million)
Fig. 21: Global Breast Cancer Drugs Market, for Ribociclib2 018-2030 (USD Million)
Fig. 22: Global Breast Cancer Drugs Market, for Palbociclib, 2018-2030 (USD Million)
Fig. 23: Global Breast Cancer Drugs Market, for Pertuzumab, 2018-2030 (USD Million)
Fig. 24: Global Breast Cancer Drugs Market, for Olaparib, 2018-2030 (USD Million)
Fig. 25: Global Breast Cancer Drugs Market, for Others, 2018-2030 (USD Million)
Fig. 26: Global Breast Cancer Drugs Market, for Hormonal Therapy, 2018-2030 (USD Million)
Fig. 27: Global Breast Cancer Drugs Market, for Selective Estrogen Receptor Modulators (SERMs), 2018-2030 (USD Million)
Fig. 28: Global Breast Cancer Drugs Market, for Aromatase Inhibitors, 2018-2030 (USD Million)
Fig. 29: Global Breast Cancer Drugs Market, for Estrogen Receptor Down regulators (ERDs), 2018-2030 (USD Million)
Fig. 30: Global Breast Cancer Drugs Market, for Chemotherapy, 2018-2030 (USD Million)
Fig. 31: Global Breast Cancer Drugs Market, for Immunotherapy, 2018-2030 (USD Million)
Fig. 32: Global Breast Cancer Drugs: Cancer Type, Movement Analysis
Fig. 33: Global Breast Cancer Drugs Market, for Hormone Receptor, 2018-2030 (USD Million)
Fig. 34: Global Breast Cancer Drugs Market, for HER2+, 2018-2030 (USD Million)
Fig. 35: Global Breast Cancer Drugs: Distribution Channel, Movement Analysis
Fig. 36: Global Breast Cancer Drugs Market, for Hospital Pharmacies, 2018-2030 (USD Million)
Fig. 37: Global Breast Cancer Drugs Market, for Retail Pharmacies, 2018-2030 (USD Million)
Fig. 38: Global Breast Cancer Drugs Market, for Others2018-2030 (USD Million)
Fig. 39: Regional Marketplace: Key Takeaways Breast Cancer Drugs Market,
Fig. 40: Regional Outlook, 2022 & 2030 Breast Cancer Drugs Market,
Fig. 41: Global Breast Cancer Drugs Market, Region Movement Analysis
Fig. 42: North America Breast Cancer Drugs Market, 2018-2030 (USD Million)
Fig. 43: U.S. Breast Cancer Drugs Market, 2018-2030 (USD Million)
Fig. 44: Canada Breast Cancer Drugs Market, 2018-2030 (USD Million)
Fig. 45: Europe Breast Cancer Drugs Market, 2018-2030 (USD Million)
Fig. 46: Germany Breast Cancer Drugs Market, 2018-2030 (USD Million)
Fig. 47: UK Breast Cancer Drugs Market, 2018-2030 (USD Million)
Fig. 48: France Breast Cancer Drugs Market, 2018-2030 (USD Million)
Fig. 49: Italy Breast Cancer Drugs Market, 2018-2030 (USD Million)
Fig. 50: Spain Breast Cancer Drugs Market, 2018-2030 (USD Million)
Fig. 51: Denmark Breast Cancer Drugs Market, 2018-2030 (USD Million)
Fig. 52: Sweden Breast Cancer Drugs Market, 2018-2030 (USD Million)
Fig. 53: Norway Breast Cancer Drugs Market, 2018-2030 (USD Million)
Fig. 54: Asia Pacific Breast Cancer Drugs Market, 2018-2030 (USD Million)
Fig. 55: Japan Breast Cancer Drugs Market, 2018-2030 (USD Million)
Fig. 56: China Breast Cancer Drugs Market, 2018-2030 (USD Million)
Fig. 57: India Breast Cancer Drugs Market, 2018-2030 (USD Million)
Fig. 58: Australia Breast Cancer Drugs Market, 2018-2030 (USD Million)
Fig. 59: South Korea Breast Cancer Drugs Market, 2018-2030 (USD Million)
Fig. 60: Thailand Breast Cancer Drugs Market, 2018-2030 (USD Million)
Fig. 61: Latin America Breast Cancer Drugs Market, 2018-2030 (USD Million)
Fig. 62: Brazil Breast Cancer Drugs Market, 2018-2030 (USD Million)
Fig. 63: Mexico Breast Cancer Drugs Market, 2018-2030 (USD Million)
Fig. 64: Argentina Breast Cancer Drugs Market, 2018-2030 (USD Million)
Fig. 65: Middle East and Africa Breast Cancer Drugs Market, 2018-2030 (USD Million)
Fig. 66: South Africa Breast Cancer Drugs Market, 2018-2030 (USD Million)
Fig. 67: Saudi Arabia Breast Cancer Drugs Market, 2018-2030 (USD Million)
Fig. 68: UAE Breast Cancer Drugs Market, 2018-2030 (USD Million)
Fig. 69: Kuwait Breast Cancer Drugs Market, 2018-2030 (USD Million)

Companies Mentioned

  • Novartis Ag
  • Pfizer, Inc
  • Merck Kgaa
  • Janssen Pharmaceuticals, Inc.
  • Celgene Corporation, Inc.
  • Genzyme Corporation
  • F. Hoffmann-La Roche Ltd
  • Astrazeneca
  • Abbvie Inc.
  • Bristol-Myers Squibb Company
  • Macrogenics, Inc.
  • Celldex Therapeutics
  • Onyx Pharmaceuticals Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages180
PublishedJune 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 29.26 Billion
Forecasted Market Value ( USD ) by 2030 $ 58.69 Billion
Compound Annual Growth Rate9.0%
Regions CoveredGlobal
No. of Companies Mentioned13

Related Topics

Related Reports

Breast Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Platform-based, Instrument-based), By Type (Imaging, Biopsy, Genomic Tests, Blood Tests), By Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030 - Product Image

Breast Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Platform-based, Instrument-based), By Type (Imaging, Biopsy, Genomic Tests, Blood Tests), By Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030

  • Report
  • 190 Pages
  • Global
From
Global Breast Cancer Drugs Market by Type (Anti-Metabolites, Aromatase Inhibitor, CDK 4/6 Inhibitor), Distribution Channel (Ambulatory Surgical Centres, Clinics, Hospitals) - Forecast 2024-2030 - Product Image

Global Breast Cancer Drugs Market by Type (Anti-Metabolites, Aromatase Inhibitor, CDK 4/6 Inhibitor), Distribution Channel (Ambulatory Surgical Centres, Clinics, Hospitals) - Forecast 2024-2030

  • Report
  • 197 Pages
  • Global
From
Global Breast Cancer Diagnostics Market by Technique (Imaging, Molecular Testing, Tissue Biopsy Tests), Cancer Type (BRCA Breast Cancer, EGFR Mutation Test Breast Cancer, ER & PR Breast Cancer), Component, Diagnostic Type, End-User - Forecast 2024-2030 - Product Image

Global Breast Cancer Diagnostics Market by Technique (Imaging, Molecular Testing, Tissue Biopsy Tests), Cancer Type (BRCA Breast Cancer, EGFR Mutation Test Breast Cancer, ER & PR Breast Cancer), Component, Diagnostic Type, End-User - Forecast 2024-2030

  • Report
  • 180 Pages
  • Global
From
Global HER-2 Negative Breast Cancer - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Global HER-2 Negative Breast Cancer - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 120 Pages
  • Global
From
Global Breast Cancer Core Needle Biopsy Market Size, Share & Trends Analysis Report by Technology, End-use (Hospitals & Diagnostic Laboratories, Academic & Research Institutes), Region, and Segment Forecasts, 2023-2030 - Product Image

Global Breast Cancer Core Needle Biopsy Market Size, Share & Trends Analysis Report by Technology, End-use (Hospitals & Diagnostic Laboratories, Academic & Research Institutes), Region, and Segment Forecasts, 2023-2030

  • Report
  • 120 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.